Form 4: CytomX Therapeutics Director Granted 38,000 Stock Options

James R. Meyers, a Director at CytomX Therapeutics, Inc. (CTMX), was granted 38,000 stock options with an exercise price of $2.82, aligning his interests with shareholders.

Summary

• James R. Meyers, a Director of CytomX Therapeutics, Inc. (CTMX), was granted 38,000 stock options.
• The transaction date for the option grant was June 11, 2025.
• Each stock option has an exercise price of $2.82.
• The options are exercisable for 38,000 shares of CytomX Therapeutics Common Stock.
• The options have an expiration date of June 10, 2035.
• The underlying shares subject to the option will vest and become exercisable as to 100% of the total number of shares on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, contingent on continuous service as a director.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating alignment of interests and long-term commitment, though it is a routine compensation event.

Positives

• The grant of stock options to a director aligns management's interests with those of the shareholders, as the options gain value if the company's stock price increases.
• The options have a long expiration date (June 10, 2035), providing a long-term incentive for the director.

Future Outlook

The grant of stock options with a vesting schedule indicates an expectation of continued service from the director and aligns their future financial incentives with the long-term performance of CytomX Therapeutics.

Industry Context

This is a standard compensation practice in the biotechnology and pharmaceutical industries, where equity grants are commonly used to incentivize directors and executives, aligning their long-term interests with company performance and shareholder value.

Related Party Transactions

• The grant of stock options to James R. Meyers, a Director of CytomX Therapeutics, Inc., constitutes a related party transaction as it involves an equity award to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options become more valuable if the stock price increases.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation strategy that can influence overall company culture and retention of key personnel.

Next Steps

• The stock options will vest on the earlier of the first anniversary of the grant date or the 2026 Annual Meeting of Stockholders, assuming continuous service.
• Upon vesting, the director will have the right to exercise the options and purchase common stock at the exercise price.

Key Dates

Keywords

CytomX Therapeutics, CTMX, stock option, insider transaction, Form 4, director compensation, equity grant, vesting